123 related articles for article (PubMed ID: 12951334)
1. Induction of telithromycin resistance in Streptococcus pneumoniae.
Kaieda S; Okitsu N; Yano H; Hosaka Y; Nakano R; Okamoto R; Takahashi H; Inoue M
J Antimicrob Chemother; 2003 Oct; 52(4):736-7. PubMed ID: 12951334
[No Abstract] [Full Text] [Related]
2. Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003.
Farrell DJ; Felmingham D
Antimicrob Agents Chemother; 2004 May; 48(5):1882-4. PubMed ID: 15105150
[TBL] [Abstract][Full Text] [Related]
3. Macrolide and ketolide resistance with Streptococcus pneumoniae.
Doern GV
Med Clin North Am; 2006 Nov; 90(6):1109-24. PubMed ID: 17116439
[TBL] [Abstract][Full Text] [Related]
4. Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae.
Jorgensen JH; Crawford SA; McElmeel ML; Whitney CG
Antimicrob Agents Chemother; 2004 Feb; 48(2):605-7. PubMed ID: 14742216
[TBL] [Abstract][Full Text] [Related]
5. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
Mazzariol A; Koncan R; Vitali LA; Cornaglia G
J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of the first telithromycin-resistant Streptococcus pneumoniae isolate in Germany.
Reinert RR; van der Linden M; Al-Lahham A
Antimicrob Agents Chemother; 2005 Aug; 49(8):3520-2. PubMed ID: 16048973
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.
Tessier PR; Mattoes HM; Dandekar PK; Nightingale CH; Nicolau DP
Antimicrob Agents Chemother; 2005 Jan; 49(1):188-94. PubMed ID: 15616295
[TBL] [Abstract][Full Text] [Related]
8. High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae.
Wolter N; Smith AM; Low DE; Klugman KP
Antimicrob Agents Chemother; 2007 Mar; 51(3):1092-5. PubMed ID: 17210764
[TBL] [Abstract][Full Text] [Related]
9. Telithromycin (Ketek) for respiratory infections.
Med Lett Drugs Ther; 2004 Aug; 46(1189):66-8. PubMed ID: 15314586
[No Abstract] [Full Text] [Related]
10. Telithromycin-resistant Streptococcus pneumoniae.
Goldstein F; Vidal B; Kitzis MD
Emerg Infect Dis; 2005 Sep; 11(9):1489-90. PubMed ID: 16673517
[No Abstract] [Full Text] [Related]
11. High prevalence of the ermB gene among erythromycin-resistant streptococcus pneumoniae isolates in Germany during the winter of 2000-2001 and in vitro activity of telithromycin.
Kresken M; Henrichfreise B; Bagel S; Brauers J; Wiedemann B
Antimicrob Agents Chemother; 2004 Aug; 48(8):3193-5. PubMed ID: 15273149
[TBL] [Abstract][Full Text] [Related]
12. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study.
Mazzariol A; Koncan R; Bahar G; Cornaglia G
J Chemother; 2007 Oct; 19(5):500-7. PubMed ID: 18073148
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.
Farrell DJ; Morrissey I; Bakker S; Buckridge S; Felmingham D
Antimicrob Agents Chemother; 2004 Aug; 48(8):3169-71. PubMed ID: 15273142
[TBL] [Abstract][Full Text] [Related]
14. Comparative activity of telithromycin against macrolide-resistant isolates of Streptococcus pneumoniae: results of two years of the PROTEKT surveillance study.
Schito GC; Marchese A; Elkharrat D; Farrell DJ;
J Chemother; 2004 Feb; 16(1):13-22. PubMed ID: 15077994
[TBL] [Abstract][Full Text] [Related]
15. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3.
Jenkins SG; Farrell DJ; Patel M; Lavin BS
J Infect; 2005 Dec; 51(5):355-63. PubMed ID: 15950288
[TBL] [Abstract][Full Text] [Related]
16. Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phenotypes.
Edelstein PH
Clin Infect Dis; 2004 May; 38 Suppl 4():S322-7. PubMed ID: 15127365
[TBL] [Abstract][Full Text] [Related]
17. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.
Jenkins SG; Brown SD; Farrell DJ
Ann Clin Microbiol Antimicrob; 2008 Jan; 7():1. PubMed ID: 18190701
[TBL] [Abstract][Full Text] [Related]
18. Will resistance to ketolides develop in Streptococcus pneumoniae?
Leclercq R
J Infect; 2002 Feb; 44 Suppl A():11-6. PubMed ID: 12150490
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
Walsh F; Carnegy F; Willcock J; Amyes S
J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
[TBL] [Abstract][Full Text] [Related]
20. Time-kill study of the activity of telithromycin against macrolide-resistant Streptococcus pneumoniae Isolates with 23S rRNA mutations and changes in ribosomal proteins L4 and L22.
Reinert RR; Al-Lahham A
Antimicrob Agents Chemother; 2005 Jul; 49(7):3011-3. PubMed ID: 15980387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
